ADPT
Adaptive Biotechnologies Corp
NASDAQ · Healthcare · Biotechnology · US
$23.95
−0.29%Oct 14, 2026, 20:05 UTC
Adaptive Biotechnologies announced that it will report its third-quarter 2026 financial results after market close on November 4, 2026, followed by a webcast conference call.
Source:Sep 25, 2026, 12:03 UTC
Adaptive Biotechnologies highlighted the role of its highly sensitive MRD testing in the new International Myeloma Society consensus definition of cure for multiple myeloma, presented at the IMS 23rd Annual Meeting in Glasgow, Scotland.
Source:Sep 17, 2026, 12:00 UTC
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for Multiple Myeloma to strengthen routine MRD assessment recommendations and specifically reference Adaptive Biotechnologies' clonoSEQ assay.
Source:Aug 18, 2026, 00:15 UTC
Harlan Robins, co-founder of Adaptive Biotechnologies, raised $15 million for a new startup focused on rethinking how AI trains on scientific data.
Source:Jul 31, 2026, 19:45 UTC
Adaptive Biotechnologies announced the planned separation of its Immune Medicine business to become a pure-play MRD diagnostics company.
Source:Jul 29, 2026, 22:05 UTC
Adaptive Biotechnologies strengthened its balance sheet through a $340 million convertible note offering.
Jul 29, 2026, 20:05 UTC
Adaptive Biotechnologies reported financial results for the second quarter of 2026.
Jul 29, 2026, 00:00 UTC
Harlan Robins departed as Chief Scientific Officer of Adaptive Biotechnologies Corp and became a strategic consultant, effective July 24, 2026.
Jun 16, 2026, 07:55 UTC
Adaptive Biotechnologies Corporation announced its intention to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Jun 15, 2026, 20:05 UTC
Adaptive Biotechnologies announced a proposed offering of $250 million aggregate principal amount of convertible senior notes due 2031 in a private offering to qualified institutional buyers.